Viralytics Company Overview and Cancer Research Advancements

Viralytics is an Australian biotechnology company that was acquired by Merck in 2016 for $1.08 billion. The company's primary focus was on developing cancer treatments based on oncolytic viruses.

Viralytics was founded in 1995 and was initially focused on developing treatments for various types of cancer. The company's technology was based on the use of oncolytic viruses to selectively target and kill cancer cells.

One of the company's most notable advancements was the development of the oncolytic virus, CAVATAK, which was in clinical trials for the treatment of cervical cancer.

Viralytics was a biotechnology company that focused on developing oncolytic viruses to treat cancer.

The company's research and development efforts were centered around its lead product, CVA21.

CVA21 was a vesicular stomatitis virus (VSV) engineered to selectively target and kill cancer cells.

This approach was based on the idea that cancer cells can be selectively targeted and killed using a virus that is engineered to replicate only within cancer cells.

Viralytics' scientists had a deep understanding of the molecular mechanisms underlying cancer cell growth and the immune system's response to cancer.

Their research led to the development of a proprietary technology platform that enabled the creation of oncolytic viruses like CVA21.

This platform allowed for the precise engineering of viruses to target specific types of cancer.

Merck has acquired Viralytics for $394m, a deal that will make Viralytics a wholly owned subsidiary of Merck.

This acquisition will give Merck full rights to Viralytics' investigational oncolytic immunotherapy CAVATAK (CVA21), which is being evaluated as both an intratumoral and intravenous agent.

CAVATAK is also being studied in combination with Merck's anti-PD-1 therapy KEYTRUDA (pembrolizumab) in a clinical trial.

A study is investigating the use of the CAVATAK and KEYTRUDA combination in melanoma, prostate, lung, and bladder cancers.

Dr. Roy Baynes, Merck's senior vice-president and head of clinical development, believes that Viralytics' approach to targeting cancer cells complements Merck's immuno-oncology strategy.

Curious to learn more? Check out: Keytruda Copay Assistance

Oncolytic Immunotherapies are a promising area of cancer research, and Viralytics is at the forefront of this field. The company's lead product, CAVATAK, is a proprietary formulation of the common Coxsackievirus Type A21 (CVA21), which has demonstrated anti-tumour activity and a promising safety profile in Phase 2 clinical trials.

CAVATAK targets cancer cells by attaching itself to a protein highly expressed on their surface, ICAM-1. This allows it to directly infect, multiply within, and destroy a wide range of cancer cells. After cancer cells lysis, thousands of viral progeny can spread and replicate, potentially activating the body's own immune system.

The mechanism of action of CAVATAK involves oncolysis through preferential targeting of cells that over-express ICAM-1 and/or DAF compared to normal cells, as well as an immunological involvement that promotes tumour inflammation and prompts the patient's immune system to attack the infected cancer cells.

In early clinical trials, CAVATAK showed favourable results in treating Stage IV melanoma patients. In a Phase 1 trial, five out of nine patients experienced transient/stable reductions in injected tumour volume or tumour stabilization. Two patients displayed stable disease as assessed by RECIST following CT scan evaluation.

Worth a look: Does Insurance Cover Wigs for Cancer Patients

Here are some key results from the Phase 1 trial:

Viralytics' Oncolytic Immunotherapy technology is already protected by numerous patents worldwide, positioning the company for success in a market with a projected annual value of $35 billion by 2023.